Literature DB >> 10190779

Metastatic breast cancer: the role of chemotherapy.

G W Sledge1, K D Miller.   

Abstract

Treatment of metastatic breast cancer remains in flux. A flurry of new chemotherapeutic agents with activity against this disease has been identified in recent years, yet breast cancer remains a cause of significant morbidity and mortality. The taxanes in particular appear to hold promise for improved outcome and, in fact, are the treatment of choice for salvage therapy. Using the taxanes in high-dose regimens, with stem cell transplantation, in alternative schedules, and in combination regimens, including with biologic treatments, is the focus of future potential advances. Continued investigative energy and the discovery of novel drugs and therapeutic approaches for addition to established techniques hopefully will improve outcomes in the next generation of treatment strategies for metastatic breast cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10190779

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  2 in total

1.  Characterization of Prox1 and VEGFR-3 expression and lymphatic phenotype in normal organs of mice lacking p50 subunit of NF-κB.

Authors:  Michael J Flister; Lisa D Volk; Sophia Ran
Journal:  Microcirculation       Date:  2011-02       Impact factor: 2.628

2.  Prognostic factors for patients with hepatic metastases from breast cancer.

Authors:  L Wyld; E Gutteridge; S E Pinder; J J James; S Y Chan; K L Cheung; J F R Robertson; A J Evans
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.